Karimah Es Sabar
Quark Venture Inc.
In her role as CEO & Partner at Quark Venture Ms. Es Sabar is also a Director of the Global Health Sciences Fund (GHS Fund), which was co-established with GF Securities, Hong Kong and which is one of the largest health sciences venture funds.
Prior to joining Quark Venture, Ms. Es Sabar led the Centre for Drug Research and Development (CDRD) as Canada’s national translation centre. She has an expansive global career spanning multi-national pharmaceutical/biotechnology companies (most notably Sanofi Pasteur), start- ups, not-for-profit organizations and venture investment. Ms. Es Sabar has extensive international experience and network, as well as leadership in marketing, business development, investment, strategic alliances, global collaborations and public private partnerships. She has raised new public and private sector funding in excess of $180M, brought products to market, and has also developed and executed innovation and translation strategies in the life science sector and in biotech investment.
Ms. Es Sabar has received multiple awards and recognitions for her pioneering work, including Canada’s Most Powerful Women: Top 100 Award. She holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management; an MSc degree in Neurochemistry from the Institute of Psychiatry University of London, England ‒ and a BSc Joint Honours degree in Biochemistry/Chemistry from the University of Salford in Manchester, England.
Ms. Es Sabar has served on numerous boards including the National Research Council Canada, Providence Healthcare Research Institute and the Vancouver Prostate Centre, as well as several health technology companies. Currently she is Board Chair for TRIUMF Innovations. As a thought leader on innovation ecosystems, she is a frequent keynote speaker.